Huchzermeyer H, Münzenmaier R
Medizinische Klinik, Klinikum Minden.
Dtsch Med Wochenschr. 1995 Feb 24;120(8):252-6. doi: 10.1055/s-2008-1055341.
Acute cholestatic hepatitis developed in two patients, a 58-year-old man and a 54-year-old woman, who had been treated for hypercholesterolaemia with the cholesterol-synthesis inhibitor lovastatin for 3 years and 2 months, respectively. Both of them at first complained only of tiredness and loss of appetite, but then developed jaundice with colourless stool and dark urine. Alkaline phosphatase concentration rose up to maximally 1227 and 569 U/l, gamma-GT to 403 and 410 U/l, respectively. The transaminases and glutamate dehydrogenase were also elevated, while serum cholinesterase had fallen to 2346 and 2418 U/l, respectively. Histological examination of liver biopsies 6 months and 4 weeks, respectively, after onset of jaundice also suggested drug-toxic liver damage. There was no evidence for other causes. After lovastatin had been discontinued the various cholestasis parameters regressed only slowly.
两名患者出现了急性胆汁淤积性肝炎,一名58岁男性和一名54岁女性,他们分别使用胆固醇合成抑制剂洛伐他汀治疗高胆固醇血症3年零2个月和2年零2个月。他们起初都只是抱怨疲劳和食欲不振,但随后出现黄疸,伴有大便无色和尿液深色。碱性磷酸酶浓度分别最高升至1227和569 U/l,γ-谷氨酰转移酶分别升至403和410 U/l。转氨酶和谷氨酸脱氢酶也升高,而血清胆碱酯酶分别降至2346和2418 U/l。黄疸出现后分别在6个月和4周进行的肝活检组织学检查也提示药物性肝损伤。没有证据表明存在其他病因。停用洛伐他汀后,各种胆汁淤积参数仅缓慢消退。